Cardiac Wire #220 October 24, 2024
The State of Cardiology | Oral GLP-1’s CV Potential
Cardiac Wire #219 October 21, 2024
Questioning Semaglutide’s CVD Impact | iCardio Clearance
Cardiac Wire #218 October 17, 2024
AFib Inhaler’s Mixed Results | Spironolactone Spirals
Cardiac Wire #217 October 10, 2024
AstraZeneca’s New Lp(a) Candidate | Aortic Stenosis AI Breakthrough
Cardiac Wire #216 October 7, 2024
Finerenone’s Early HF Impact | Rivus’ Obesity HFpEF Potential
Cardiac Wire #215 October 3, 2024
Mavacamten’s HFpEF Potential | Swiss Army Surgery
Cardiac Wire #214 September 30, 2024
Preventing Post-Cancer CVD | J&J’s Cardiometabolic Shutdown
Cardiac Wire #213 September 26, 2024
Istaroximes’ Cardiogenic Shock Impact | RPM Scrutiny
Cardiac Wire #212 September 23, 2024
Edgewise Enters HCM Arena | Preventive LAAO
Cardiac Wire #211 September 19, 2024
Questioning PCI’s LV Effect | An ICE AI Alliance
Cardiac Wire #210 September 16, 2024
America’s Hypertension Problem | Why Not Screen For AFib
Cardiac Wire #209 September 12, 2024
AFib Across the U.S. | Early Cholesterol Control
Cardiac Wire #208 September 9, 2024
Continuing Beta-Blockers | AI Aortic Stenosis Screening
Cardiac Wire #207 September 5, 2024
Asundexian’s OCEANIC Setback | ESC 2024 Highlights
Cardiac Wire #206 September 3, 2024
Vutrisiran Shines | Hypertension Paradigm Shift
Cardiac Wire #205 August 29, 2024
Leqvio Monotherapy | TCM for Arrhythmia
Cardiac Wire #204 August 26, 2024
Tirzepatide Impact | Olpasiran Makes Waves
Cardiac Wire #203 August 22, 2024
J&J’s HFrEF Expansion | Edwards’ AR Acquisition
Cardiac Wire #202 August 19, 2024
